Generic Drug Development CDMO

Introduction: For any company preparing to file an Abbreviated New Drug Application (ANDA), a Comparative Dissolution Study for ANDA is […]

Introduction Scaling a GLP-1 analog from preclinical synthesis to Good Manufacturing Practice (GMP) kilogram-scale manufacturing involves moving beyond small-scale discovery

Introduction Supporting a poorly soluble generic API requires an integrated Chemistry, Manufacturing, and Controls (CMC) framework that combines systematic reference-listed

Introduction Executing a successful Generic Metered Dose Inhaler (MDI) ANDA Development program requires a comprehensive weight-of-evidence regulatory framework that demonstrates

Introduction Impurity profiling and structural elucidation for generic small-molecule injectable Abbreviated New Drug Applications (ANDAs) is an essential analytical activity

Introduction Accelerating Health Canada ANDS Submission timelines requires a coordinated regulatory strategy that integrates pre-filing bioequivalence data verification, technical auditing

Introduction Bioanalytical Method Development and Validation at a CDMO provides the quantitative foundation needed to establish pharmacokinetic equivalence between generic

Introduction Executing Generic Ophthalmic Suspension ANDA Development requires a comprehensive technical strategy that integrates qualitative and quantitative formulation sameness (Q1/Q2),

Introduction Impurity Control Strategies Under ICH Q3A and Q3B establish a risk-based regulatory framework used by global health authorities to